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The diagnosis of congenital melanocytic naevi (CMN) covers a wide phenotypic spectrum. Small single CMN are very common birthmarks, present in approximately 1% of all neonates,[1](#bjd18106-bib-0001){ref-type="ref"}, [2](#bjd18106-bib-0002){ref-type="ref"}, [3](#bjd18106-bib-0003){ref-type="ref"}, [4](#bjd18106-bib-0004){ref-type="ref"}, [5](#bjd18106-bib-0005){ref-type="ref"}, [6](#bjd18106-bib-0006){ref-type="ref"} are not associated with extracutaneous abnormalities, and have a very low risk of transformation to melanoma.[7](#bjd18106-bib-0007){ref-type="ref"}, [8](#bjd18106-bib-0008){ref-type="ref"}, [9](#bjd18106-bib-0009){ref-type="ref"}, [10](#bjd18106-bib-0010){ref-type="ref"} At the other end of the spectrum, multiple CMN (defined as two or more melanocytic naevi at birth) can cover up to 80% of the body surface area, can be associated with serious extracutaneous abnormalities, such as congenital neurological disease,[11](#bjd18106-bib-0011){ref-type="ref"}, [12](#bjd18106-bib-0012){ref-type="ref"}, [13](#bjd18106-bib-0013){ref-type="ref"}, [14](#bjd18106-bib-0014){ref-type="ref"} typical facial features,[15](#bjd18106-bib-0015){ref-type="ref"} underdevelopment of fat and muscle in naevoid areas, and endocrinological disturbance.[16](#bjd18106-bib-0016){ref-type="ref"} The risk of melanoma in childhood varies with the congenital phenotype (both cutaneous and neurological), between 1% and 12% in prospective studies.[13](#bjd18106-bib-0013){ref-type="ref"}, [17](#bjd18106-bib-0017){ref-type="ref"} Where CMN are associated with extracutaneous abnormalities, the term CMN syndrome[15](#bjd18106-bib-0015){ref-type="ref"} is preferred to the historical term neurocutaneous melanosis, as the latter does not encompass the whole range of neurological associations, and critically does not distinguish between benign congenital neurological disease, and acquired central nervous system melanoma.

The molecular basis of multiple CMN and CMN syndrome was only recently clearly established. As this is a sporadic condition and had been described in one twin of monozygotic pairs,[18](#bjd18106-bib-0018){ref-type="ref"}, [19](#bjd18106-bib-0019){ref-type="ref"} it was proposed 25 years ago to be due to a postzygotic mutation *in utero*, and therefore to represent a mosaic disorder.[20](#bjd18106-bib-0020){ref-type="ref"} However, reports of occasional familial cases[21](#bjd18106-bib-0021){ref-type="ref"}, [22](#bjd18106-bib-0022){ref-type="ref"}, [23](#bjd18106-bib-0023){ref-type="ref"} later led to the hypothesis that multiple CMN were due to paradominant inheritance with allelic loss,[24](#bjd18106-bib-0024){ref-type="ref"} and later still to a patchy manifestation of a polygenic trait.[25](#bjd18106-bib-0025){ref-type="ref"} In the interim, many variants were described in single samples of CMN from cohorts of patients, including *TP53,* [26](#bjd18106-bib-0026){ref-type="ref"} *NRAS,* [26](#bjd18106-bib-0026){ref-type="ref"}, [27](#bjd18106-bib-0027){ref-type="ref"}, [28](#bjd18106-bib-0028){ref-type="ref"}, [29](#bjd18106-bib-0029){ref-type="ref"}, [30](#bjd18106-bib-0030){ref-type="ref"} *BRAF,* [31](#bjd18106-bib-0031){ref-type="ref"}, [32](#bjd18106-bib-0032){ref-type="ref"}, [33](#bjd18106-bib-0033){ref-type="ref"}, [34](#bjd18106-bib-0034){ref-type="ref"}, [35](#bjd18106-bib-0035){ref-type="ref"} *GNAQ* [29](#bjd18106-bib-0029){ref-type="ref"} and *MC1R*.[26](#bjd18106-bib-0026){ref-type="ref"}, [36](#bjd18106-bib-0036){ref-type="ref"} A systematic study established that the same mutation was present in multiple affected tissues from one individual, and absent from unaffected tissues including blood,[37](#bjd18106-bib-0037){ref-type="ref"} which is the cornerstone of demonstrating clonality and, therefore, by inference, likely causal mutations in mosaicism where there are multiple lesions. This study demonstrated *NRAS* mutations affecting codon 61 \[p.(Q61K) or (p.Q61R)\] in 12 of 15 patients. Subsequent studies of a rarer phenotype, multiple naevus spilus‐type CMN, revealed different changes in *NRAS* \[p.(Q61H), p.(G13R), p.(Q61L)\].[38](#bjd18106-bib-0038){ref-type="ref"}, [39](#bjd18106-bib-0039){ref-type="ref"} Since then, further publications of single samples from patients with CMN have confirmed the predominance of *NRAS* mutations in large or giant CMN.[40](#bjd18106-bib-0040){ref-type="ref"}, [41](#bjd18106-bib-0041){ref-type="ref"}

The role of *BRAF* in multiple CMN has been even more recently clarified. Previous studies had demonstrated *BRAF* p.(V600E) mutations in single samples of CMN,[31](#bjd18106-bib-0031){ref-type="ref"}, [32](#bjd18106-bib-0032){ref-type="ref"}, [33](#bjd18106-bib-0033){ref-type="ref"}, [34](#bjd18106-bib-0034){ref-type="ref"}, [35](#bjd18106-bib-0035){ref-type="ref"}, [40](#bjd18106-bib-0040){ref-type="ref"} with two reported cases of *BRAF* activation secondary to a chromosomal translocation involving 7q, demonstrated in melanocytes derived from the main CMN.[35](#bjd18106-bib-0035){ref-type="ref"} Furthermore, multiple CMN is an established feature in patients with ring chromosome 7, with evidence of somatic mosaicism leading to significant gain of chromosome 7 within the CMN.[42](#bjd18106-bib-0042){ref-type="ref"}, [43](#bjd18106-bib-0043){ref-type="ref"} However, a role for *BRAF* in CMN was debated, with no evidence for *BRAF* variants in true congenital naevi in one study.[27](#bjd18106-bib-0027){ref-type="ref"} A single case of multiple CMN where mutant *BRAF* was detected in more than one naevus from the same patient has now been published,[44](#bjd18106-bib-0044){ref-type="ref"} confirming clonality in that patient as opposed to a second hit, and effectively confirming the pathogenesis in previous reports of multiple CMN or CMN syndrome. Single cases of fusion transcripts as potential conduits of multiple CMN have also been recently described, one each of *ZEB2‐ALK* and *SOX5‐RAF1*.[45](#bjd18106-bib-0045){ref-type="ref"}

Genotype has already been demonstrated to be clinically relevant in terms of management, with *NRAS*‐mutant melanoma treated with MEK inhibition leading to symptomatic improvement, though not cure.[46](#bjd18106-bib-0046){ref-type="ref"} We sought to explore genotype--phenotype and genotype--outcome associations in a large cohort of patients, to improve our understanding of the effect of genotype on clinical outcome, and to assess whether routine genotyping is relevant in routine clinical practice.

Patients and methods {#bjd18106-sec-0007}
====================

Genotypic and phenotypic characterization of patients {#bjd18106-sec-0008}
-----------------------------------------------------

Children with CMN seen in the paediatric dermatology department of a tertiary referral centre between January 2015 and January 2018 were offered participation in a genotyping study, approved by the local NHS Research Ethics Committee (London Bloomsbury). This involved a blood sample for *MC1R* genotyping, and/or a single 4‐mm punch skin biopsy for genotyping for *NRAS* and *BRAF* mutational 'hotspots', and/or genotyping from archival formalin‐fixed paraffin‐embedded (FFPE) tissue.

DNA was extracted by standard methods, and directly without skin culture from fresh skin samples (DNeasy Blood & Tissue Kit; Qiagen, Hilden, Germany), or from FFPE CMN tissue (Maxwell^®^ RSC DNA FFPE Kit, Promega Corporation, Madison, WI, U.S.A.). All patients underwent deep clinical phenotyping, including assessment of facial features as previously published.[15](#bjd18106-bib-0015){ref-type="ref"} Phenotyping was by two different classifications, an in‐house classification as previously published,[13](#bjd18106-bib-0013){ref-type="ref"}, [17](#bjd18106-bib-0017){ref-type="ref"}, [37](#bjd18106-bib-0037){ref-type="ref"} and a recent consensus classification from the literature.[47](#bjd18106-bib-0047){ref-type="ref"}

DNA was obtained from peripheral blood samples in 75 individuals, and from 156 samples of CMN in 134 individuals. Skin DNA was initially genotyped in the hospital diagnostic laboratory for hotspot mutations in *NRAS* leading to amino acid changes in codon 61, and in *BRAF* affecting codon 600. Samples that were negative for both of these hotspots ('double wild‐type') were additionally sequenced for *NRAS* mutations affecting codons 12 and 13. Genotyping for *NRAS* was by two methods, namely touchdown polymerase chain reaction (PCR) and Sanger sequencing (sensitivity down to 10% mutant allele detection), and High Resolution Melt (HRM) (sensitivity down to 1%). Genotyping for *BRAF* mutations was by three diagnostic‐grade methods initially, as at the time *BRAF* mutation was not an established cause of multiple CMN: Sanger sequencing, HRM, and allele‐specific real‐time PCR (*BRAF* Codon 600 Mutational Analysis Kit, EntroGen, Inc., Woodland Hills, CA, U.S.A.). The latter was later discontinued, as the concordance between HRM and real‐time PCR was 100%.Where a *BRAF* p.(V600E) mutation was found, a second biopsy from a separate skin lesion was offered to the patient, as well as a blood sample, and both were tested by the same methods. *MC1R* genotyping was performed in all patients by Sanger sequencing of lymphocyte DNA extracted from whole blood, as previously described.[36](#bjd18106-bib-0036){ref-type="ref"} Genotyping results for *NRAS, BRAF* and *MC1R* were ultimately available for 117, 96 and 75 patients, respectively, as in some cases results were not possible from FFPE tissue, or patients did not wish to have either a blood test or biopsy.

Statistical analysis {#bjd18106-sec-0009}
--------------------

Genotyping data were included as independent variables in multiple logistic regression modelling of clinical phenotype variables using IBM SPSS Statistics 24·0 (IBM, Armonk, NY, U.S.A.). Specifically, the associations modelled were between *NRAS* and *MC1R* genotype (mutant or wild‐type) and projected adult size (PAS) of the largest CMN, typical facies and congenital neurological disease on magnetic resonance imaging (MRI). A statistical correction was applied for multiple testing, which reduced the *P*‐value for significance to *P* \< 0·0125. *BRAF* genotype was not used to model phenotype statistically as the total number of patients was too low, and similarly melanoma as an outcome was not modelled separately.

Cell culture and cell treatment {#bjd18106-sec-0010}
-------------------------------

Naevus cells were isolated and cultured from fresh CMN tissue. Briefly, tissue was incubated in trypsin 0·25% for 4 h at 37 °C to allow removal of the epidermis. Following this, the reticular dermis was dissected out and digested in dispase/collagenase for a further 6 h, before neutralizing the digest with complete melanocyte media \[Ham\'s F‐10 Nutrient Mix (11550043; Thermo Fisher Scientific, Waltham, MA, U.S.A.) supplemented with Ultroser G, fetal bovine serum, tissue plasminogen activator, cholera toxin, human stem cell factor, 3‐isobutyl‐1‐methylxanthine, fibroblast growth factor, endothelin, penicillin/streptomycin and amphotericin B\]. A single‐cell suspension was achieved by filtering cells through a 70‐μm followed by a 40‐μm cell strainer before seeding cells in complete media into tissue culture flasks. When flasks reached 70% confluence, DNA was extracted directly from pelleted cells washed once with phosphate‐buffered saline using DNeasy Tissue Kit (Qiagen). Sanger sequencing was performed as described above. BRAF V600E naevus cells were additionally seeded onto laminin‐coated slides, fixed with 4% paraformaldehyde and permeabilized with 0·01% Triton X‐100, before blocking for 1 h at room temperature in 10% bovine serum albumin. Cells were incubated overnight at 4 °C with BRAF V600E antibody 1 : 1000 (ab200535; Abcam, Cambridge, U.K.), with appropriate negative controls, followed by incubation with goat anti‐rabbit IgG‐conjugated Alexa Fluor 488 secondary antibody (A‐11034; Thermo Fisher Scientific) for 1 h at room temperature. Slides were washed and mounted, and imaged using a Zeiss Axio Observer four‐colour fluorescence microscope (Carl Zeiss Microscopy GmbH, Jena, Germany).

Results {#bjd18106-sec-0011}
=======

Demographic and phenotypic characterization of the cohort {#bjd18106-sec-0012}
---------------------------------------------------------

Details of the demographic and phenotypic characterization are shown in Table [1](#bjd18106-tbl-0001){ref-type="table"}. This cohort is at the more serious phenotypic end of the spectrum of children with CMN, with 76% having multiple CMN (two or more at birth), 59% and 32% with PAS of the largest naevus \> 20 cm and \> 60 cm, respectively, and 29% with congenital neurological involvement on screening MRI; 69% had at least three typical facial features of CMN syndrome. Eight cases with melanoma were included, seven of whom were in our recent melanoma cohort review.[17](#bjd18106-bib-0017){ref-type="ref"}

###### 

Summary of genotype and phenotype of cohort

+-----------+-----------+--------------------------------------------+-----------------------------+-----------------------------+-----------------------------+--------------+------------------------------+----------------+
| Sex       | MRI       | Neurological and/or developmental problems | *NRAS* genotype             | *BRAF* genotype             | *MC1R* genotype             | Multiple CMN | Postnatal/ recurrent nodules | Classic facies |
+===========+===========+============================================+=============================+=============================+=============================+==============+==============================+================+
| Male      | Normal    | Yes                                        | Mutation positive           | *BRAF* p.(V600E)            | At least one *MC1R* variant | Multiple     | Present                      | Present        |
|           |           |                                            |                             |                             |                             |              |                              |                |
| 53 (39·6) | 67 (71·3) | 23 (18·3)                                  | 80 (68·4)                   | 7 (7·3)                     | 47 (62·7)                   | 94 (75·8)    | 26 (22·4)                    | 66 (68·8)      |
|           |           |                                            |                             |                             |                             |              |                              |                |
|           |           |                                            | p.(Q61K) 59 (73·8)          |                             |                             |              |                              |                |
|           |           |                                            |                             |                             |                             |              |                              |                |
|           |           |                                            | p.(Q61R) 17 (21·3)          |                             |                             |              |                              |                |
|           |           |                                            |                             |                             |                             |              |                              |                |
|           |           |                                            | p.(Q61H) 3 (3·8)            |                             |                             |              |                              |                |
|           |           |                                            |                             |                             |                             |              |                              |                |
|           |           |                                            | p.(G13R) 1 (1·25)           |                             |                             |              |                              |                |
+-----------+-----------+--------------------------------------------+-----------------------------+-----------------------------+-----------------------------+--------------+------------------------------+----------------+
| Female    | Abnormal  | None                                       | Mutation negative 37 (31·6) | Mutation negative 89 (92·7) | No *MC1R* variants          | Single       | Absent                       | Absent         |
|           |           |                                            |                             |                             |                             |              |                              |                |
| 81 (60·4) | 27 (28·7) | 103 (81·7)                                 |                             |                             | 28 (37·3)                   | 30 (24·2)    | 89 (76·7)                    | 30 (31·3)      |
+-----------+-----------+--------------------------------------------+-----------------------------+-----------------------------+-----------------------------+--------------+------------------------------+----------------+
| Missing   | Missing   | Missing                                    | Missing                     | Missing                     | Missing                     | Missing      | Missing                      | Missing        |
|           |           |                                            |                             |                             |                             |              |                              |                |
| *n* = 0   | *n* = 40  | *n* = 8                                    | *n* = 17                    | *n* = 38                    | *n* = 59                    | *n* = 10     | *n* = 19                     | *n* = 38       |
+-----------+-----------+--------------------------------------------+-----------------------------+-----------------------------+-----------------------------+--------------+------------------------------+----------------+

All data are presented as *n* (%) unless otherwise stated. MRI, magnetic resonance imaging; CMN, congenital melanocytic naevi.
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Genotypic characterization of the cohort {#bjd18106-sec-0013}
----------------------------------------

Genotyping results are shown in Table [1](#bjd18106-tbl-0001){ref-type="table"} *. NRAS* variants were detected in 68%, all but one affecting codon 61. The mutational profile revealed a predominance of p.(Q61K) (74% of the 68%) over p.(Q61R) (21% of the 68%), consistent with previous smaller studies,[28](#bjd18106-bib-0028){ref-type="ref"}, [37](#bjd18106-bib-0037){ref-type="ref"} but differing from the mutational profile for non‐CMN‐associated melanoma, where these two variants have equal frequency.[48](#bjd18106-bib-0048){ref-type="ref"}, [49](#bjd18106-bib-0049){ref-type="ref"} For p.(Q61K) this was usually due to c.(C181A); however, two patients carried small indels, c.180_181delinsTA and c.181_183delinsAAG, the former not previously described in CMN but described once in melanoma,[50](#bjd18106-bib-0050){ref-type="ref"} and the latter described once before in three cases of CMN[40](#bjd18106-bib-0040){ref-type="ref"} and once in melanoma.[51](#bjd18106-bib-0051){ref-type="ref"} Additionally, three patients had *NRAS* p.(Q61H) mutations, all of which were in naevus spilus‐type CMN, two of whom were previously published in a naevus spilus‐type CMN study.[38](#bjd18106-bib-0038){ref-type="ref"} Similarly, the one patient with a mutation affecting a different codon \[p.(G13R)\] was previously published with a naevus spilus‐type CMN phenotype.[38](#bjd18106-bib-0038){ref-type="ref"} Eleven patients with mutant *NRAS*, and two patients who were double wild‐type, were previously published in our original CMN genotype study.[37](#bjd18106-bib-0037){ref-type="ref"}

*BRAF* c.1799T\>A*,* p.(V600E) was detected in naevi from 7% (*n* = 7) of the cohort, and was also found in a second biopsy of a separate CMN in all patients where it was possible to obtain this tissue (five of seven).

In the remaining 25% of patients, both *NRAS* and *BRAF* were not mutated at these hotspots (double wild‐type), and also did not carry variants affecting *NRAS* codons 12 or 13. This is again consistent with previous studies of CMN but inconsistent with the mutational profile of *NRAS*‐mutant melanoma where codons 12/13 contribute 8% to the total *NRAS* variants.[49](#bjd18106-bib-0049){ref-type="ref"}

Genotype--phenotype analysis {#bjd18106-sec-0014}
----------------------------

In five of seven *BRAF*‐mutant patients there was a striking multinodular clinical phenotype within the largest CMN (Fig. [1](#bjd18106-fig-0001){ref-type="fig"}, detailed clinical phenotype in Table [2](#bjd18106-tbl-0002){ref-type="table"}), with densely packed, uniform multiple benign nodules appearing both pre‐ and postnatally. This is highly suggestive that this rare genotype is linked to this rare multinodular phenotype. From what we have observed, this phenotype can be distinguished from other types of multinodularity by the uniformity of the size and appearance of the nodules within a patient, and the frequent presence of a mobile, firm‐to‐hard lump within a softer exterior to each of the nodules. Multiple similar uniform pre‐ and postnatal nodules were also seen in 4% of double wild‐type patients, but not in *NRAS*‐mutant patients.

![(a--e) Cutaneous phenotype of the five *BRAF*‐mosaic patients with a multinodular phenotype. (f--i) Cutaneous phenotype of two *BRAF*‐mosaic patients without the multinodular phenotype, both presenting with a medium congenital melanocytic naevus and \> 200 smaller naevi \[patient 6 (f, g) from Table [2](#bjd18106-tbl-0002){ref-type="table"}, and patient 7 (h, i) from Table [2](#bjd18106-tbl-0002){ref-type="table"}\].](BJD-182-434-g001){#bjd18106-fig-0001}

###### 

Detailed phenotype of *BRAF*‐mutant multiple congenital melanocytic naevus (CMN)

<table><thead><tr class="header"><th>Patient</th><th>Sex</th><th>Age (years)</th><th>Neuro‐development</th><th>Krengel classification<a href="#bjd18106-bib-0047" data-ref-type="ref">47</a></th><th>Classic facies</th><th>Single or multiple</th><th>MRI</th><th>Skin samples tested, <em>n</em></th><th>Comorbidities</th></tr></thead><tbody><tr class="odd"><td>1</td><td>Female</td><td>3</td><td>Speech delay</td><td><p>CMN PAS</p><p>L2 &gt; 30–40 cm</p><p>CMN localization</p><p>Trunk: upper back, middle back</p><p>Satellites</p><p>S3 C1 R0 N2 H2</p></td><td>Yes</td><td>Multiple</td><td>Normal</td><td>2</td><td>Nil</td></tr><tr class="even"><td>2</td><td>Male</td><td>8</td><td>Normal</td><td><p>CMN PAS</p><p>G1 &gt; 40–60 cm</p><p>CMN localization</p><p>Trunk: middle back, lower back, abdomen, flank, gluteal region, genital region</p><p>Satellites</p><p>S2 C0 R0 N2 H0</p></td><td>Yes</td><td>Multiple</td><td>Not performed</td><td>2</td><td>Nil</td></tr><tr class="odd"><td>3</td><td>Female</td><td>0·5</td><td>Normal</td><td><p>CMN PAS</p><p>L2 &gt; 30–40 cm</p><p>CMN localization</p><p>Trunk: upper back, middle back</p><p>Satellites</p><p>S2 C0 R0 N2 H1</p></td><td>N/A</td><td>Multiple</td><td>Intraparenchymal melanosis</td><td>2</td><td>Nil</td></tr><tr class="even"><td>4</td><td>Female</td><td></td><td>Normal</td><td><p>CMN PAS</p><p>G2 &gt; 60 cm</p><p>CMN localization</p><p>Trunk: gluteal region; extremities: thigh; lower leg</p><p>Satellites</p><p>S3 C0 R1 N2 H2</p></td><td>No</td><td>Multiple</td><td>Not performed</td><td>1</td><td>Nil</td></tr><tr class="odd"><td>5</td><td>Female</td><td></td><td>Normal</td><td><p>CMN PAS</p><p>M1 1·5–10 cm</p><p>CMN localization</p><p>Extremities: hand</p><p>Satellites</p><p>S1 C1 R0 N2 H0</p></td><td>Missing</td><td>Multiple</td><td>Not performed</td><td>1</td><td>Nil</td></tr><tr class="even"><td>6</td><td>Male</td><td>4</td><td>Speech delay</td><td><p>CMN PAS</p><p>L1 &gt; 20–30 cm</p><p>CMN localization</p><p>Trunk: lower back, gluteal region</p><p>Satellites</p><p>S3 C0 R0 N0 H1</p></td><td>No</td><td>Multiple</td><td>Normal</td><td>2</td><td>Nil</td></tr><tr class="odd"><td>7</td><td>Female</td><td>1</td><td>Global DD</td><td><p>CMN PAS</p><p>L2 &gt; 30–40 cm</p><p>CMN localization</p><p>Extremities: upper leg</p><p>Satellites</p><p>S3 C0 R0 N0 H0</p></td><td>Yes</td><td>No</td><td>Intraparenchmyal melanosis</td><td>2</td><td><p>Infantile encephalopathicepilepsy</p><p>Epithelioid melanocytoma on knee</p></td></tr></tbody></table>

MRI, magnetic resonance imaging; F, female; M, male; PAS, projected adult size; N/A, not applicable; DD, developmental delay.
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Analysis of the association between *NRAS* mutant genotype (vs. *NRAS* wild‐type) and the PAS of the main CMN did not reveal a statistically significant association, with *NRAS* as the commonest mutation at all sizes of CMN, and the commonest in both single and multiple CMN. However, inspection of the raw data revealed that the percentage of patients with *NRAS‐*mutant CMN is fairly constant in all size groups (52--76%) except where PAS is \> 60 cm, when 91% of patients (30 of 33) were *NRAS*‐mutant (Fig. [2](#bjd18106-fig-0002){ref-type="fig"}2a--c, Table [1](#bjd18106-tbl-0001){ref-type="table"}).

![Interaction between congenital melanocytic naevus (CMN) projected adult size and genotype, for (a) the whole cohort (*n* = 134); (b) single naevus only; (c) multiple naevi only. While the *NRAS* mutant genotype is the commonest at all sizes of CMN, there is enrichment of this genotype specifically in the subgroup with projected adult size \> 60cm. WT, wild‐type; PAS, projected adult size.](BJD-182-434-g002){#bjd18106-fig-0002}

Typical facial features of CMN syndrome were significantly less common in double wild‐type patients compared with those carrying *NRAS* or *BRAF* mutations (*P* = 0·006). However, the numbers in the double wild‐type group with facial phenotyping were relatively small (*n* = 20), and this finding should therefore be interpreted as preliminary at this stage.

Genotype--outcome analysis {#bjd18106-sec-0015}
--------------------------

No significant associations were found between genotype and presence of congenital neurological disease on screening MRI in the first 6--12 months of life (Fig. [3](#bjd18106-fig-0003){ref-type="fig"}a). Cases of melanoma were described in the *NRAS*‐mutant and one in the double wild‐type group, and although no cases were described in *BRAF*‐mutant patients this is statistically compatible with the rarity of this genotype (Fig. [3](#bjd18106-fig-0003){ref-type="fig"}b). Cases of melanoma were described across all *MC1R* genotyping groups (wild‐type, heterozygous, compound heterozygous/homozygous) (Table [1](#bjd18106-tbl-0001){ref-type="table"}). Numbers of melanoma were too small to model this statistically.

![Interaction between genotype and (a) congenital neurological disease, and (b) melanoma incidence. No difference is observed between different groups. WT, wild‐type; MRI, magnetic resonance imaging; CNS, central nervous system.](BJD-182-434-g003){#bjd18106-fig-0003}

Histological characterization of *BRAF‐*mutant nodules {#bjd18106-sec-0016}
------------------------------------------------------

Histopathological analysis of nodules demonstrated a pattern distinct from the classic proliferative nodules seen frequently in CMN, in which the proliferation is of naevus cells. In these *BRAF*‐mutant cases the proliferation instead appeared to be within the subcutis and adipose tissue, with the naevus itself stretched across the top of the underlying proliferation, and a recurrent finding of septa‐like bands of naevus cells within the adipose tissue (Fig. [4](#bjd18106-fig-0004){ref-type="fig"}). This pattern has previously been described historically,[52](#bjd18106-bib-0052){ref-type="ref"} but was not at that time connected to genotype.

![Histology of *BRAF* congenital melanocytic naevi (CMN) and nodules in four patients presenting with a multinodular CMN, showing proliferation of adipose tissue, with the naevus stretched across the top of the underlying proliferation, and a recurrent finding of septa‐like bands of naevus cells within the adipose tissue in patients 1, 3, 4 and 5 from Table [2](#bjd18106-tbl-0002){ref-type="table"}.](BJD-182-434-g004){#bjd18106-fig-0004}

*NRAS/BRAF* mutations are heterozygous in naevus cells {#bjd18106-sec-0017}
------------------------------------------------------

Sanger sequencing of DNA extracted directly from cultured naevus cells obtained from two patients, one with mutant *NRAS* p.(Q61R) and one with mutant *BRAF* p.(V600E), demonstrates heterozygosity for *NRAS/BRAF* mutations in naevus cells, with an increase in somatic mutation load in comparison with Sanger sequencing of DNA extracted directly from whole tissue from CMN (Fig. [5](#bjd18106-fig-0005){ref-type="fig"}a, b), confirming that the naevus cells are the mutant cells.

![Sanger sequencing trace of DNA extracted directly from (a) congenital melanocytic naevus (CMN) tissue (upper) and DNA extracted from cultured naevus cells (lower) from the same patient, demonstrating *BRAF* c.1799T\>A, p.(V600E) in both, which appears low‐level somatic in whole tissue and heterozygous in naevus cells. (b) A similar phenomenon is observed in naevus cells cultured directly from a patient with *NRAS* c183A\>G, p.(Q61R). Immunocytochemistry of BRAF p.(V600E) naevus cells shows pancytoplasmic uniform expression of BRAF V600E (green) in all naevus cells. Cells are counterstained with Hoechst stain (blue) and Alexa Fluor 647‐conjugated phalloidin antibody (red). BRAF V600E negative control at original magnification × 20 (c), and BRAF V600E immunostaining at × 20 (d) and × 63 (e).](BJD-182-434-g005){#bjd18106-fig-0005}

Naevus cells express mutant BRAF p.(V600E) in *BRAF* p.(V600E) CMN {#bjd18106-sec-0018}
------------------------------------------------------------------

Immunocytochemistry of primary naevus cells cultured from a *BRAF* p.(V600E) CMN demonstrates uniform expression of mutant BRAF protein in all naevus cells throughout the cytoplasm (Fig. [5](#bjd18106-fig-0005){ref-type="fig"}5d--f).

Discussion {#bjd18106-sec-0019}
==========

We confirm here in a large cohort of patients that *NRAS* mutations affecting codon 61 are the commonest cause of CMN, found in 68%, with *BRAF* mutations affecting codon 600 a much rarer cause at 7%. These percentages are comparable with the original description of 12 of 15 cases (80%) being *NRAS*,[37](#bjd18106-bib-0037){ref-type="ref"} and with 77% and 8% *NRAS* and *BRAF*, respectively, described in another cohort of 66 patients with CMN.[40](#bjd18106-bib-0040){ref-type="ref"} *BRAF* mutations as the first (or at least primary driver) hit as the cause of multiple CMN has only very recently been demonstrated,[44](#bjd18106-bib-0044){ref-type="ref"} and has effectively confirmed previous reports of likely *BRAF* mosaicism in previous studies.[40](#bjd18106-bib-0040){ref-type="ref"}

*NRAS* and *BRAF* hotspot activating mutations have been found to be almost invariably mutually exclusive in melanoma and in other malignant tumours that commonly harbour these mutations.[53](#bjd18106-bib-0053){ref-type="ref"}, [54](#bjd18106-bib-0054){ref-type="ref"}, [55](#bjd18106-bib-0055){ref-type="ref"}, [56](#bjd18106-bib-0056){ref-type="ref"}, [57](#bjd18106-bib-0057){ref-type="ref"}, [58](#bjd18106-bib-0058){ref-type="ref"}, [59](#bjd18106-bib-0059){ref-type="ref"}, [60](#bjd18106-bib-0060){ref-type="ref"}, [61](#bjd18106-bib-0061){ref-type="ref"} Rare incidences of concurrent *NRAS* and *BRAF* mutations have been described, for example in two cases of melanoma in a large series (0·7%),[62](#bjd18106-bib-0062){ref-type="ref"} in one of 15 nodular melanomas,[63](#bjd18106-bib-0063){ref-type="ref"} in one of 14 melanomas,[64](#bjd18106-bib-0064){ref-type="ref"} in four of 60 cases of melanoma arising within an existing naevus,[65](#bjd18106-bib-0065){ref-type="ref"} and in 1·6% in a large series of 484 melanomas; however in this last study, cloning of a single *NRAS/BRAF* mutant cell line revealed the mutations were mutually exclusive at single‐cell level.[64](#bjd18106-bib-0064){ref-type="ref"} Although a number of studies have adopted sensitive techniques for *NRAS/BRAF* mutational analysis over Sanger sequencing for their improved ability to detect mutant alleles at low frequency,[34](#bjd18106-bib-0034){ref-type="ref"}, [55](#bjd18106-bib-0055){ref-type="ref"}, [64](#bjd18106-bib-0064){ref-type="ref"}, [66](#bjd18106-bib-0066){ref-type="ref"} many studies have relied on Sanger sequencing alone.[27](#bjd18106-bib-0027){ref-type="ref"}, [30](#bjd18106-bib-0030){ref-type="ref"}, [53](#bjd18106-bib-0053){ref-type="ref"}, [54](#bjd18106-bib-0054){ref-type="ref"}, [59](#bjd18106-bib-0059){ref-type="ref"}, [67](#bjd18106-bib-0067){ref-type="ref"}, [68](#bjd18106-bib-0068){ref-type="ref"}, [69](#bjd18106-bib-0069){ref-type="ref"} In our study, the use of at least two highly sensitive methods of mutation detection, and the unbiased genotyping strategy, can confirm mutual exclusivity of these mutations in CMN.

*BRAF* mutations appear to be commonly but not exclusively associated with a distinctive highly nodular phenotype, with characteristic clinical and histological appearances in five of seven cases. A previous cohort study demonstrated a significantly increased frequency of dermal/subcutaneous nodules in *BRAF‐* compared with *NRAS*‐mutated CMN,[40](#bjd18106-bib-0040){ref-type="ref"} and the recent case of *BRAF* mosaicism also demonstrated a somewhat multinodular phenotype.[44](#bjd18106-bib-0044){ref-type="ref"} NRAS is known to have multiple effector pathways, only one of which signals via BRAF, and it may be that the balance of these effectors is responsible for the differences in phenotype. Alternatively, constitutive BRAF activation via the p.(V600E) amino acid change may induce a different pattern of MAPK pathway overactivity. The apparent proliferation of subcutaneous adipose tissue as opposed to the naevus cells themselves suggests a non‐cell‐autonomous effect of the mutant naevus cells on the surrounding tissues. This finding is supported to some degree by a recent study of the histopathological features of acquired rather than congenital MN, which demonstrated differential morphology and cellular distribution in association with *BRAF* p.(V600E) expression.[70](#bjd18106-bib-0070){ref-type="ref"}

There is an interesting relationship between genotype and size of the main naevus, which has only become apparent in this large cohort. Previously it has been suggested that *BRAF* mutations are associated with smaller CMN, and *NRAS* with larger CMN.[30](#bjd18106-bib-0030){ref-type="ref"}, [34](#bjd18106-bib-0034){ref-type="ref"}, [66](#bjd18106-bib-0066){ref-type="ref"} In one study, *BRAF* mutations were found in zero of 19 large CMN compared with six of 20 small/medium CMN[66](#bjd18106-bib-0066){ref-type="ref"} and a statistically significant increased frequency of *BRAF* mutations in smaller sized CMN has been demonstrated in two papers, the first identifying *BRAF* mutations in 26 of 42 small CMN compared with only five of 20 medium CMN, and the second observing *BRAF* V600E in nine of 37 medium CMN compared with zero of 18 giant CMN.[34](#bjd18106-bib-0034){ref-type="ref"} This apparent association was later called into question by a further paper describing *BRAF* V600E mutations in five of 66 CMN -- in one of 20 patients with large CMN, and four of 36 patients with giant CMN.[40](#bjd18106-bib-0040){ref-type="ref"} In our cohort, *NRAS* was clearly the commonest mutation in all PAS groups of CMN; however, a potential reason for the previous conflicting results is that in the group of \> 60‐cm PAS there is a much higher frequency of *NRAS* mutations. As we know that these largest naevi are likely to be the first to form embryologically,[71](#bjd18106-bib-0071){ref-type="ref"} the potential explanation for this is that *NRAS* mutations are more easily tolerated at that stage of embryogenesis than the non‐*NRAS* causes.

Neurological involvement has been described in two patients with *BRAF* p.(V600E) mutant 'giant' CMN.[40](#bjd18106-bib-0040){ref-type="ref"} Data here from a large number of patients with MRI scans demonstrate a uniform pattern of congenital neurological abnormalities across the three genotypic groups. Similarly, data on melanoma in this cohort, although the numbers are small, do not suggest genotypic differences in outcome. No *BRAF*‐mutant patients had been diagnosed with melanoma, but this could be due to the small numbers rather than a genuinely differential genotypic effect. Going forward, the statistical significance of typical facies in patients appearing less commonly in those with double wild‐type genotype will need to be determined in a larger cohort. Potential limitations of this study are related to the numbers, as in particular the numbers of *BRAF* mutant patients are small. This will be resolved with a continuous prospective collection of this cohort.

We conclude here that *NRAS* mutations are the commonest cause of CMN, and of any size of CMN, being particularly common in the group with PAS \> 60 cm. *BRAF* mutations can be a cause of multiple CMN, can be seen in any size group, and have a strong but not exclusive association with a distinct multinodular phenotype. Critically, clinical outcomes do not appear to be different among genotypic groups, with clear data on congenital neurological disease, and suggestive data for melanoma. Therefore, genotyping does not need to form part of routine clinical care. However, genotyping should be performed where melanoma is suspected, and particularly where melanoma treatment is required.
